edc-fsc-gvc-2018-keynote

6 / 10

N o v e m b e r 1 4 - 1 5 , 2 0 1 8 | R o m e , I t a l y
Note:
Page 19
Euro Diabetes Congress 2018, Global Vaccines Congress 2018
& Food Science Conference 2018 Archives of General Internal Medicine | ISSN: 2591-7951| Volume 2
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
&
&
NUTRITION, FOOD SCIENCE & TECHNOLOGY
International Conference on
DIABETES, ENDOCRINOLOGY & NURSING MANAGEMENT
World Congress on
VACCINES & VACCINATION
3rd Global Congress on
Mamdouh Abdulrhman, Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C6-016
HONEY IN TYPE 2 DIABETES MELLITUS
Honey, as a natural substance produced by honey bees, has many benefits
for health and nutrition. The aim of the present study is to test the effects
of honey consumption, as a sole treatment, in patients with type 2 DM. Twenty
adult patients with type 2 DM volunteered to stop their medications and to use
honey as an alternative and sole treatment of their diabetes and its associat-
ed metabolic derangements. Their mean age was 46.5 years and they were of
both sexes. The mean duration of their diabetes was 5.1 years. At baseline; the
mean HbA1C value was of 9.7%, the mean BMI was 32.5; twelve patients had
systemic hypertension, twelve had dyslipidemia, ten had symptoms of periph-
eral neuritis, one had retinopathy with retinal hemorrhage, and four had coro-
nary heart disease. All patients stopped their medicines and consumed honey
in a minimum dose of 2 g/kg/day assuming body weight 75 kg. The duration
of honey intervention, without medicines, ranged from 0.42 to 14 years, with
a mean of 2.8 years. Ten patients continued the trial for more than one year,
5 completed one year intervention and 5 discontinued the intervention before
one year. The only cause of discontinuation of the intervention was persistent
hyperglycemia. Long-term honey intervention, without medicines, resulted in
persistent hyperglycemia, persistent dyslipidemia, body weight reduction and
improvement of macro-vascular complications. No patient developed coma,
cerebral strokes or serious infections. The renal functions remained normal
during honey intervention. Two patients, who did not receive anti-diabetic med-
icines after discontinuation of honey, developed DKA one and four months af-
ter discontinuation of honey, after periods of interventions of 0.5 and 2.6 years,
respectively. This small sampled study showed that honey, as a sole treatment
of type 2 DM, is superior to the current medications, and its benefits may out-
weigh the risks.
Biography
Mamdouh Abdulrhman has received his PhD from
Ain Shams University, Egypt in 1993. Currently,
he is working as a professor in pediatrics in Ain
Shams University. His research has been mainly
focused on clinical uses of bee honey. Based on his
research he has been considered by the German
Apitherapy Society as an Expert and Counselor in
the clinical use of bee honey. He is serving as an
expert Reviewer for journals like Journal of diabe-
tes and its complications, Journal of Clinical Nu-
trition, European Journal of Clinical Nutrition and
Journal of diabetes and metabolic disorders.
Mamdouh Abdulrhman
Ain Shams University, Egypt